Forsteo licensed for use in men

The licence for Forsteo (teriparatide) has been extended to include the treatment of osteoporosis in men at increased risk of fracture.

The recommended dose is 20 micrograms administered once daily by subcutaneous injection in the thigh or abdomen.

Further information: Lilly 01256 315000

Go to: MIMS drug entry for Forsteo

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Early emollient use does not prevent eczema in children

Early emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...